Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 14/20 | 0.51 |
| ▸ | NPC1 | O15118 | 13/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31731985 | 0.77 | RAB9A (0.67) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3313092 | 0.76 | RAB9A (0.65) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2079932 | 0.76 | PTGS1 (0.58) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1723055 | 0.74 | PTGS1 (0.52) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL171008 | 0.74 | PTGS1 (0.52) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13218389 | 0.74 | PTGS1 (0.52) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL794230 | 0.74 | RAB9A (0.58) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2482387 | 0.74 | PTGS1 (0.52) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL20893047 | 0.74 | PTGS1 (0.52) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL755953 | 0.74 | RAB9A (0.58) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432995-B1 | — | — | None | — | — | US | disclosed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| CN-120040444-A | Imidazopyridine compound and preparation method and application thereof | 上海复旦张江生物医药股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-115315425-B | Preparation method and intermediate of substituted imidazo [1,2-a ] pyridine-2-ylamide compound | 上海复旦张江生物医药股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| CN-118063491-A | Imide catalyst auxiliary agent, polyimide film and preparation method | 中国科学院化学研究所 | 2024-05-24 | — | — | CN | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| CN-116262739-A | Nitrogen-containing aryl derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-6329415-B1 | INHIBIT RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| US-6319921-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, CROHN'S DISEASE ULCERATIVE COLITIS, PSORIASIS, GRAFT VERSUS HOST DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS AND DIABETES | BOERHINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010039290-A1 | Aromatic heterocyclic compounds and their use as anti-inflammatory agents | REGAN JOHN R (US) | 2001-11-08 | — | — | US | disclosed |
| EP-1147104-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6228881-B1 | THIOPHENE DERIVATIVE CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-05-08 | — | — | US | disclosed |
| EP-1028953-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-2000043384-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| US-6080763-A | INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES, E.G., TUMOR NECROSIS FACTOR AND INTERLEUKIN-1; USEFUL TO TREAT CHRONIC INFLAMMATORY DISEASE; AUTOIMMUNE DISEASES, E.G. RHEUMATOID ARTHRITIS, OSTEOPOROSIS; PYRAZOLYLUREAS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-06-27 | — | — | US | disclosed |
| WO-1999023091-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| EP-0876337-A2 | NEW LH-RH ANTAGONISTS WITH IMPROVED EFFECTIVENESS | ASTA Medica Aktiengesellschaft (DE) | 1998-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | PIK3CG 3510/4885PTGS1 4353/4885PTGS2 4174/4885 |
| US-20010039290-A1 | Aromatic heterocyclic compounds and their use as anti-inflammatory agents | IL1A, IL1B, TNF | PIK3CG 2167/4885PTGS1 41/4885PTGS2 112/4885 |
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | PIK3CG 3445/4885PTGS1 651/4885PTGS2 575/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | PIK3CG 3030/4885PTGS1 3025/4885PTGS2 4221/4885 |
| US-20240285611-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | PIK3CG 1862/4885PTGS1 311/4885PTGS2 583/4885 |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | BAX, BCL2, BCL3 | PIK3CG 1862/4885PTGS1 311/4885PTGS2 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.